PRIME-XS open call for proposals

NewsGuard 100/100 Score

The PRIME-XS consortium is a strategic collaboration of research groups from twelve international institutes, leading in the field of proteomics. PRIME-XS provides an infrastructure of state-of-the-art proteomics technologies to the European biological and biomedical research community.
PRIME-XS is providing open and competitive access to their proteomics instrumentation and expertise.

Over 50 state-of-the-art mass spectrometers and associated proteomics technologies are available at six access facilities. Different access facilities will host research projects with different requirements.
The six transnational access facilities of PRIME-XS are:

  • Netherlands Proteomics Centre Utrecht The Netherlands
  • VIB Proteomics Unit Ghent Belgium
  • Functional Genomics Center Zurich Switzerland
  • CRG/UPF Proteomics Unit Barcelona Spain
  • Cambridge Center for Proteomics Cambridge United Kingdom
  • CEA Proteomics technological platform Grenoble France

WHAT CAN BE APPLIED FOR

European researchers can request access to proteomics techniques at the six access facilities of PRIME-XS via an online application. Researchers can choose a preferential access facility where the project should be carried out and propose the proteomics technology they would like to use.
Users of the access facilities can get practical support with final sample preparation and staff of PRIME-XS will perform the proteomics data acquisition. Users will be able to visit the access facility, gain experience on sample preparation, sample analysis and data handling and analysis.
The costs for execution of the proposals are funded by PRIME-XS as part of the European 7th Framework Programme.

SUBMISSION OF PROJECT PROPOSALS

As of July 5, 2011, researchers in all EU member states and associated countries can submit their

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Microfluidic chips advance neurodegenerative disease research